digoxigenin bisdigitoxoside 是一种具有细胞毒性的抗癌药物。
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
地高辛 | digoxin | 20830-75-5 | C41H64O14 | 780.951 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-4,5-二羟基-6-甲基四氢吡喃-2-基]氧基-12,14-二羟基-10,13-二甲基-1,2,3,4,5,6,7,8,9,11,12,15,16,17-十四氢环戊烯并[a]菲-17-基]-5H-呋喃-2-酮 | Digoxigenin mono-digitoside | 5352-63-6 | C29H44O8 | 520.664 |
The effects of three cyclodextrins (α-, β-, γ-CyD) on the acid hydrolysis of digoxin were examined. From the high performance liquid chromatographic tracing of each of the four components (digoxin, bisdigitoxoside, monodigitoxoside, digoxigenin) in reaction mixtures, the individual rate constants (k1-k6) were determined by analogue computer simulation. The hydrolysis was suppressed by CyDs in the order of β->γ->α-CyD, where β-CyD inhibited the appearance rates of digoxigenin (k3, k5, and k6) significantly. In the dissolution study of digoxin tablets, the increase in dissolution rate and decrease in acid hydrolysis were attained by inclusion complexation. The data are presented suggesting that CyDs are useful for improving the oral bioavailability of digoxin.